Yonlada Nawilaijaroen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Yonlada Nawilaijaroen has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Jenna L. Cash
Centre for Inflammation Research, Institute for Regeneration and Repair, University of Edinburgh
2 shared publications - Alastair Morris Kilpatrick
University of Edinburgh
1 shared publication - Andrea Caporali
Institute of Neuroscience and Cardiovascular Research, University of Edinburgh, 47 Little France Crescent, Edinburgh EH16 4TJ, UK
1 shared publication - Antonella Pellicoro
Centre for Inflammation Research, Institute for Regeneration and Repair, University of Edinburgh
1 shared publication Asok Biswas
Department of Pathology, Western General Hospital
1 shared publication- Charlotte A. Dawson
Affiliations Centre for Snakebite Research and Interventions, Liverpool School of Tropical Medicine, Liverpool, United Kingdom, Department of Tropical Disease Biology, Liverpool School of Tropical Medicine, Liverpool, United Kingdom
1 shared publication
Latest Publications
- Open Access
- 11 November 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (46)
MC1R determines healing outcomes in acute and chronic cutaneous wounds
Chronic wounds (CWs) represent a major clinical challenge, characterized by persistent inflammation and failed repair. While proresolving pathways are known to regulate inflammatory responses, their potential dysfunction in CWs remains unexplored. Here, we identify dysregulation of the pro-opiomelanocortin-melanocortin 1 receptor (POMC–MC1R) axis as a common feature across pressure ulcers, venous ulcers, and diabetic ulcers. Using MC1Re/e mice lacking functional MC1R, we demonstrate impaired wound healing marked by delayed reepithelialization and increased neutrophil extracellular traps—pathological features observed in human CWs. To investigate MC1R’s therapeutic potential, we developed a new murine CW model that replicates human pathology, presenting as nonhealing, exudate-rich ulcers. Topical application of the MC1R-selective agonist BMS-470539 restored healing by reducing exudate production, stimulating vascularization, and enabling reepithelialization. The critical role of MC1R was further evidenced by MC1Re/e mice, which developed more severe ulcers with excessive exudate and NETosis. In acute wound studies, we found that topical MC1R agonist enhanced wound bed perfusion and lymphatic drainage through increased angiogenesis and lymphangiogenesis and reduced scarring by modulating fibroblast phenotype. Together, these findings establish the MC1R/POMC axis as a fundamental regulator of skin repair and identify promising therapeutic strategies to drive healing.
- 11 November 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (46)
Open AccessMC1R determines healing outcomes in acute and chronic cutaneous wounds
Chronic wounds (CWs) represent a major clinical challenge, characterized by persistent inflammation and failed repair. While proresolving pathways are known to regulate inflammatory responses, their potential dysfunction in CWs remains unexplored. Here, we identify dysregulation of the pro-opiomelanocortin-melanocortin 1 receptor (POMC–MC1R) axis as a common feature across pressure ulcers, venous ulcers, and diabetic ulcers. Using MC1Re/e mice lacking functional MC1R, we demonstrate impaired wound healing marked by delayed reepithelialization and increased neutrophil extracellular traps—pathological features observed in human CWs. To investigate MC1R’s therapeutic potential, we developed a new murine CW model that replicates human pathology, presenting as nonhealing, exudate-rich ulcers. Topical application of the MC1R-selective agonist BMS-470539 restored healing by reducing exudate production, stimulating vascularization, and enabling reepithelialization. The critical role of MC1R was further evidenced by MC1Re/e mice, which developed more severe ulcers with excessive exudate and NETosis. In acute wound studies, we found that topical MC1R agonist enhanced wound bed perfusion and lymphatic drainage through increased angiogenesis and lymphangiogenesis and reduced scarring by modulating fibroblast phenotype. Together, these findings establish the MC1R/POMC axis as a fundamental regulator of skin repair and identify promising therapeutic strategies to drive healing.
- Open Access
Establishing a preclinical chronic wound model to characterise the pathophysiology of snakebite envenoming
Summary: Snakebite claims 138,000 lives a year with an additional 400,000 patients left permanently disabled or disfigured1. Morbidity following envenoming includes the development of chronic wounds around the bite site. The understanding of the underlying pathophysiology of chronic snakebite wounds has been severely limited by the historical reliance on a preclinical model that only captures acute local envenoming pathology. Through the application of three medically important snake venoms (Echis ocellatus, Bothrops atrox and Naja nigricollis) to a recently developed preclinical model of chronic wounds, we have been able to characterise key features of venom wounds. We have been able to show that venom wounds share consistencies with non-venom induced preclinical wounds, and also display unique characteristics such as extracellular matrix degradation and eosinophilic infiltrate. This model will not only serve to increase our understanding the underlying pathophysiology of venom wounds, but will also provide a platform for exploring therapeutic interventions to reduce or resolve snakebite wounds.
Open AccessEstablishing a preclinical chronic wound model to characterise the pathophysiology of snakebite envenoming
Summary: Snakebite claims 138,000 lives a year with an additional 400,000 patients left permanently disabled or disfigured1. Morbidity following envenoming includes the development of chronic wounds around the bite site. The understanding of the underlying pathophysiology of chronic snakebite wounds has been severely limited by the historical reliance on a preclinical model that only captures acute local envenoming pathology. Through the application of three medically important snake venoms (Echis ocellatus, Bothrops atrox and Naja nigricollis) to a recently developed preclinical model of chronic wounds, we have been able to characterise key features of venom wounds. We have been able to show that venom wounds share consistencies with non-venom induced preclinical wounds, and also display unique characteristics such as extracellular matrix degradation and eosinophilic infiltrate. This model will not only serve to increase our understanding the underlying pathophysiology of venom wounds, but will also provide a platform for exploring therapeutic interventions to reduce or resolve snakebite wounds.